Tag Archives: Alkermes

Xoma To Buy Failed Mural, Ending The Short, Unsuccessful Run Of The Alkermes Spinoff

By |
0 Comment

Barely 2 weeks ago, Mural Oncology(MURA) announced it would be winding down operations, and likely returning any remaining cash to shareholders. We estimated that the value to shareholders of the 2023 Alkermes(ALKS) spinoff would be slightly less than $2, a disappointing outcome, but at least not a total loss. Today, Mural announced it had agreed to be acquired… Read More »

Painting a Beautiful Mural: Alkermes Completes Spinoff Of Mural Oncology

By |
0 Comment

With a goal of becoming “a pure-play, profitable neuroscience company”, on November 15, Alkermes(ALKS) spun off its oncology business as Mural Oncology(MURA). In the tax free spinoff, Alkermes shareholders as of November 6 received one share of Mural for every ten shares owned. According to BioPharma Dive, the $275 million in cash that Mural has to start with… Read More »